Casgevy is the first gene therapy approved for sickle cell disease and transfusion-dependent beta-thalassemia in patients aged 2 and older.

The products may now carry a claim telling smokers that switching to ZYN "puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis." ...

The FDA released a list of participants for a 2-day July meeting of its Pharmacy Compounding Advisory Committee; at least 7 members have ties to peptide businesses.

The 12-month wind-down for therapeutics and 180-day transition for medical devices signal a definitive shift back to standard regulatory pathways, forcing manufacturers like Invivyd to pursue full FDA ...

When a hospital mistakenly destroyed a patient's placenta despite a signed release form, it faced a lawsuit — and a lesson in what truly constitutes "waste." ...

HbA1c level change from baseline was at least as large with bofanglutide as with semaglutide. HealthDay News — For adults with type 2 diabetes mellitus (T2DM), bofanglutide, a glucagon-like peptide-1 ...